Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA:603707)
China flag China · Delayed Price · Currency is CNY
7.89
-0.01 (-0.13%)
Sep 4, 2026, 3:00 PM CST

SHA:603707 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
2,1881,3951,0241,2101,389658.55
Trading Asset Securities
1,2501,3171,055681.991.3259.8
Cash & Short-Term Investments
3,4382,7112,0801,8921,390918.35
Cash Growth
75.09%30.35%9.94%36.12%51.34%-31.43%
Accounts Receivable
1,1871,229920.04771.68974.11897.75
Other Receivables
229.48235.35273.46230.88241.94167.88
Receivables
1,4171,4651,1941,0031,2161,066
Inventory
3,0463,2653,6754,1585,6164,894
Prepaid Expenses
-13.113.1711.988.467.98
Other Current Assets
90.0266.3284.42196.9964.1443.62
Total Current Assets
7,9917,5207,0467,2628,2946,930
Property, Plant & Equipment
1,1441,1921,1971,2351,198827.42
Long-Term Investments
90.4692.0883.2672.4861.626.39
Goodwill
122.71126.64129.51127.61125.48114.87
Other Intangible Assets
368.94410.37337.53174.1118.96123.85
Long-Term Deferred Tax Assets
142.21136.07203.25348.4101.4734.54
Long-Term Deferred Charges
904.76774.46459.55294.2494.6277.65
Other Long-Term Assets
117.7790.6853.710.3816.3182.34
Total Assets
10,88210,3439,5109,52410,0108,217

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
833.33589.12495.66537.74505.12458.87
Accrued Expenses
239.34241.87207.11294.8588.1564.56
Short-Term Debt
2,1831,4261,2361,5671,9571,571
Current Portion of Long-Term Debt
-838.158.21505.450.42-
Current Portion of Leases
-4.83----
Current Income Taxes Payable
-26.443.7229.310.448.73
Current Unearned Revenue
38.731.8359.0335.9338.2225.07
Other Current Liabilities
429.1746.2954.67116.18115.44138.56
Total Current Liabilities
3,7243,2052,0643,0862,7052,266
Long-Term Debt
17.9624.14824.16512.37997.36480.75
Long-Term Leases
58.959.3510.2813.2315.94-
Long-Term Unearned Revenue
101.37104.8884.6376.5784.9965.51
Long-Term Deferred Tax Liabilities
43.8649.8638.2837.3339.991.42
Total Liabilities
3,9463,4433,0223,7263,8432,814

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
1,6161,6161,6161,6171,6171,244
Additional Paid-In Capital
636.97587.3587.29601.02603.59987.96
Retained Earnings
4,6504,6244,2043,5403,9153,123
Treasury Stock
-20-15.01--27.75-32.82-47.3
Comprehensive Income & Other
56.8390.8584.6272.567.970.45
Total Common Equity
6,9406,9036,4925,8026,1715,378
Minority Interest
-3.54-3.54-3.51-3.47-3.4724.84
Shareholders' Equity
6,9366,8996,4885,7986,1675,403
Total Liabilities & Equity
10,88210,3439,5109,52410,0108,217

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
2,2602,3532,0792,5982,9712,051
Net Cash (Debt)
1,178358.171.13-706.06-1,581-1,133
Net Cash Growth
-31507.10%----
Net Cash Per Share
0.740.220.00-0.45-0.97-0.72
Filing Date Shares Outstanding
1,6421,6141,6161,4731,6531,543
Total Common Shares Outstanding
1,6421,6141,6161,4731,6531,543
Working Capital
4,2674,3154,9814,1755,5894,663
Book Value Per Share
4.234.284.023.943.733.49
Tangible Book Value
6,4486,3666,0255,5005,9265,139
Tangible Book Value Per Share
3.933.943.733.733.583.33
Buildings
-541.02472.9481.48448.47268.49
Machinery
-1,4831,3231,279981.72751.74
Construction In Progress
-4.72137.4479.74250.62215.26